Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Neal Shore, MD, FACS, an expert on bladder cancer
May 29th 2024

Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Neal Shore, MD, FACS, an expert on bladder cancer
May 29th 2024

NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Neal Shore, MD
Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.
Enhertu packaging | Image credit: AstraZeneca
May 29th 2024

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers

Ryan Flinn
Aiwu Ruth He, MD, PhD | Image credit: Medstar Health
May 27th 2024

Aiwu Ruth He, MD, PhD, Discusses 3-Year Survival Data for Durvalumab Plus Chemo in Biliary Tract Cancer, Other Advances

Interview by Mary Caffrey
what we're reading logo
May 24th 2024

What We’re Reading: Bird Flu Protective Gear; HPV Vaccine Protects Against Head, Neck Cancers; Tobacco Industry and Vapes

AJMC Staff
Many US dairy farms have not yet increased bird flu protections for employees despite the outbreak in cows; the human papillomavirus (HPV) vaccine is linked to a drastic reduction in head and neck cancers in adolescent boys and men; the World Health Organization recently accused tobacco companies of actively trying to hook a new generation on nicotine.
Natalie Dickson, MD, MMHC, FASCO, FACP | Image credit: Tennessee Oncology
May 20th 2024

Natalie Dickson, MD, MMHC, FASCO, FACP, of Tennessee Oncology Discusses Cutting-Edge Cancer Care Initiatives

Maggie L. Shaw
AHN logo | Image credit: Allegheny Health Network
May 20th 2024

AHN Cancer Institute Raises the Quality and Value Bar by Listening to Patients

Mary Caffrey
Stephen Schleicher, MD, MBA | Image credit: Tennessee Oncology
May 20th 2024

At Hearing on Recurring Cancer Drug Shortages, Rural Areas Come Into Focus

Peter Page
Bobby Reddy, MD | Image credit: Keri Tan
Published: May 20th 2024 | Updated: May 20th 2024

“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials

Mary Caffrey
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
May 14th 2024

Dr Mila Felder Discusses Promoting Well-Being Within an Organization

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.
Doctor talking to patient about prostate cancer | Image credit: kenchiro168 – stock.adobe.com
May 13th 2024

IMPLEMENT Study Finds Gaps in How Urologists, Oncologist View First-Line Treatment Intensification for Prostate Cancer

Hayden E. Klein
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
what we're reading logo
May 8th 2024

What We’re Reading: Rural Health Clinic Accreditation; Cancer Mortality in Black Women; COVID-19 Vaccination Campaign Savings

AJMC Staff
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
AJMC
May 6th 2024

Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America

Pankaj Kumar, MD Stephanie Parker, PharmD DeShawn Wilbern, MBA
CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
COA ADVOCACY PANEL | Image credit: COA
April 25th 2024

Galvanizing Community Oncology Through Advocacy, Empowerment, and Stewardship

Maggie L. Shaw
Coverage from the Community Oncology Alliance Community Oncology Conference, held April 4-5, 2024, in Orlando, Florida.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 25th 2024

Dr Mila Felder: Supporting Well-Being in Oncology Care Using Surveys

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses various surveys deployed within Advocate Health to promote organizational well-being.
Jeremy Bender, PhD | Image credit: Day One Biopharmaceuticals
April 25th 2024

Day One Marks Milestone in Pediatric Cancer as Tovorafenib Approved in BRAF-Mutated Low-Grade Glioma

Mary Caffrey
doctor consulting a patient in meeting in hospital for healthcare feedback or support-Happy medical or nurse with a mature person talking or speaking of test results or advice | Talia Mdlungu-peopleimages - stock.adobe.com
April 23rd 2024

Implementing Treatment Escalation Plans in Oncology Care at Admission Boosts Uptake, Study Finds

Pearl Steinzor
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
April 22nd 2024

Shawn Tuma Discusses the Dangers, Impacts of a Cyberattack on Health Care Systems

Maggie L. Shaw Pearl Steinzor
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP, highlights the biggest threats concerning a cyberattack on oncology practices.
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
April 18th 2024

Judith Alberto: COA Takes on Congress, Addresses Change Healthcare Cyberattack

Maggie L. Shaw Pearl Steinzor
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), discusses upcoming policy initiatives and the current oncology landscape amid a health care cyberattack.
Man being scanned by doctor | auremar - stock.adobe.com
April 18th 2024

Reducing Unnecessary Biopsies, Overdiagnosis in Prostate Cancer Screening

Pearl Steinzor
Integration of prostate MRI may improve the balance of patient harms and benefits in prostate cancer screening.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 17th 2024

Dr Mila Felder Shares Targeted Education Approaches to Promote Well-Being

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, highlights strategic approaches for incorporating well-being into a postpandemic oncology workforce.
CHEA logo | Image: AJMC
April 16th 2024

Center on Health Equity and Access: April 2024

Hayden E. Klein Giuliana Grossi Rose McNulty Mary Caffrey
Will Shapiro, vice president of data science, Flatiron Health
April 15th 2024

Will Shapiro Shares How Artificial Intelligence Is Benefiting Oncology Care

Hayden E. Klein Pearl Steinzor
Will Shapiro, vice president of data science at Flatiron Health, discusses how the practice is using large language models (LLMs) to increase efficiency, while ensuring there are frameworks set for safety and quality.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 11th 2024

Dr Mila Felder Explains the Benefits of a Well-Being Council in Oncology Practices

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares the importance of incorporating a culture of well-being within oncology practices.
cancer cells | Sodapeaw - stock.adobe.com
April 8th 2024

Accelerated Aging Linked to Increased Cancer Risk in Young Adults

Pearl Steinzor
Accelerated biological aging may be behind why some types of cancer are on the rise in young adults, researchers find.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 8th 2024

Dr Mila Felder Discusses How Peer Support Programs Can Help Alleviate Drug Shortage Distress

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares insights on how peer support groups can help manage psychological and emotional distress amid a national drug shortage.
Red FDA approval stamp | Image credit: chrisdorney - stock.adobe.com
April 5th 2024

Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors

Mary Caffrey Laura Joszt, MA
FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Will Shapiro, vice president of data science, Flatiron Health
April 5th 2024

Will Shapiro Discusses Ethical Challenges Across Various Artificial Intelligence Models in Oncology

Hayden E. Klein Pearl Steinzor
Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.
Jonathan E. Levitt, Esq, Frier Levitt, LLC
April 5th 2024

Jon Levitt Highlights Urgency for Stronger Employer Oversight of PBMs

Maggie L. Shaw Mary Caffrey
Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.
AJMC
April 5th 2024

Trends in Low-Value Cancer Care During the COVID-19 Pandemic

Ravi B. Parikh, MD, MPP Yasin Civelek, PhD, MS Pelin Ozluk, PhD David Debono, MD Michael J. Fisch, MD, MPH Gosia Sylwestrzak, MA Justin E. Bekelman, MD Aaron L. Schwartz, MD, PhD
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
<1
...
5678910111213
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo